GERALD&WULF&(GÖTTINGEN)(
PERSPECTIVES(OF(INTEGRATING(IMMUNOTHERAPY(IN(PTCL(TREATMENT(
ALGORITHMS(
(
While! disease! remission! can! be! achieved! by! current! chemotherapy! regimen! for! PTCL!
patients!at!subtype!and!stage!dependent!proportions,!the!disease!tends!to!recur,!associated!
with! mostly! dismal! outcome.! Immunological! mechanisms! may! provide! control! of! chemo>
refractory!disease,!demonstrated!by!the!efficacy!of!allogeneic!in!eligible!patients1,2.!Here!we!
will! review! the! current! approaches! to! PTCL! treatment! exploiting! humoral! and! cell>based!
immunotherapy,! i.e.! monoclonal! antibodies3,! immunoconjugates4,! bi>specific! antibodies,!
checkpoint!inhibition5,6!and!adoptive!immune!cell!therapy7,8.!!
!R
eferences:(
1.! Schmitz! N! NM,! Altmann! B,! Ziepert! M,! Bouabdallah! K! et! al.! Allogeneic! or! autologous!
transplantation!as!first>line!therapy!for!younger!patients!with!peripheral!T>cell!lymphoma:!Results!of!
the!interim!analysis!of!the!AATT!trial.!J(Clin(Oncol.!2015;suppl;!abstr!8507.!
2.! Schmitz! N,! Lenz! G,! Stelljes! M.! Allogeneic! hematopoietic! stem! cell! transplantation! for! T>cell!
lymphomas.!Blood.!2018;132(3):245>253.!
3.! Wulf! GG,! Altmann! B,! Ziepert! M,! et! al.! Alemtuzumab! plus! CHOP! versus! CHOP! in! elderly!
patients!with!peripheral!T>cell!lymphoma:!the!DSHNHL2006>1B/ACT>2!trial.!Leukemia.!2020.!
4.! Horwitz! S,! O'Connor! OA,! Pro! B,! et! al.! Brentuximab! vedotin! with! chemotherapy! for! CD30>
positive!peripheral!T>cell!lymphoma!(ECHELON>2):!a!global,!double>blind,!randomised,!phase!3!trial.!
Lancet.!2019;393(10168):229>240.!
5.! Wartewig! T,! Kurgyis! Z,! Keppler! S,! et! al.! PD>1! is! a! haploinsufficient! suppressor! of! T! cell!
lymphomagenesis.!Nature.!2017;552(7683):121>125.!
6.! Kwong! YL,! Chan! TSY,! Tan! D,! et! al.! PD1! blockade! with! pembrolizumab! is! highly! effective! in!
relapsed!or!refractory!NK/T>cell!lymphoma!failing!l>asparaginase.!Blood.!2017;129(17):2437>2442.!
7.! Rogers! AM,! Brammer! JE.! Hematopoietic! Cell! Transplantation! and! Adoptive! Cell! Therapy! in!
Peripheral!T!Cell!Lymphoma.!Curr(Hematol(Malig(Rep.!2020;15(4):316>332.!
8.! Scherer!LD,!Brenner!MK,!Mamonkin!M.!Chimeric!Antigen!Receptors!for!T>Cell!Malignancies.!
Front(Oncol.!2019;9:126.!
!!
!
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES